PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan

Inclusion Criteria

• •Age ≥ 18 years at index date
• •Diagnosis of mPC
• •PSMA positive
• •Received at least one dose of lutetium (177Lu) vipivotide tetraxetan on or after mPC diagnosis date
• •Exclusion criterion:
• •Current or prior participation in an investigational study within the 30-day period immediately prior to and including the index date, or within five half-lives of the investigational product (whichever is longer)